诺泰生物虚增业绩面临近5000万罚款，诺泰生物被ST

Core Viewpoint - NuoTai Bio has been penalized for financial misconduct, including inflating revenue and profits, leading to significant fines and a change in stock status to ST NuoTai [1][2] Group 1: Financial Misconduct - NuoTai Bio inflated its 2021 revenue by 30 million yuan and profit by 25.9516 million yuan, which accounted for 20.64% of the reported total profit for that year [1] - Despite the inflated figures, the company's actual performance showed a revenue increase of 13.58% to 644 million yuan, while net profit decreased by 6.52% to 115 million yuan [1] Group 2: Regulatory Actions and Penalties - The China Securities Regulatory Commission (CSRC) issued a total fine of 4.74 million yuan to NuoTai Bio for two main violations: information disclosure and fabrication of significant false content in public offering documents [2] - The actual controller of NuoTai Bio, Zhao Dezhong, was fined 18 million yuan, while other executives involved faced fines ranging from 1.5 million to 3.3 million yuan [2] Group 3: Stock Market Impact - Following the penalties, NuoTai Bio's stock was subjected to risk warnings and was suspended from trading, with its stock name changed to ST NuoTai starting July 22 [2]